Eli Lilly | LLY - Selling And Administration Expenses


Eli Lilly reported $2.93B in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Abbott USD 3.6B 330M Jun/2026
ALKERMES USD 196.64M 67.96M Jun/2026
Amgen USD 1.72B 134M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Baxter International USD 735M 7M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Drreddys Laboratories INR 14.47B 12.45B Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
J&J USD 6.42B 381M Jun/2026
Medtronic 2.96B 9M Dec/2025
Merck USD 2.67B 180M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Novartis USD 3.14B 296M Mar/2026
Novo Nordisk DKK 13.22B 4.22B Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Pfizer USD 3.41B 496M Jun/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 30.28M 606K Mar/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
Sanofi EUR 2.49B 252M Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Zoetis USD 588M 31M Mar/2026